Latest Probiotics News

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Terragen Holdings has raised A$7 million through a strategic equity raising to fund scientific research and accelerate global commercialisation, while appointing Dr Michele Allan AO as its new Chair.

Biome Australia has secured ethics approval to commence a pivotal human clinical trial of its proprietary probiotic strain BMB18, aiming to validate its benefits on digestive, sleep, and mood health.

Biome Australia has partnered with Fullscript to distribute its Activated Probiotics range across Canada, complementing its existing wholesale network and marking a key step in its international growth.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

BPH Global has reported record sales in its Indonesian seaweed operations alongside completing a $1.1 million capital raise and advancing promising R&D projects. The company is scaling its trading platform and expanding into bio-stimulants and wellness products as it enters 2026.

Terragen Holdings reports a strong quarter with an 87% increase in sales of its ruminant probiotic and advances key livestock and crop trials, positioning itself for expanded market access.

Biome Australia Limited has delivered its strongest quarterly financial performance to date, with sales revenue surging 41% year-on-year to $6.5 million and maintaining eight consecutive quarters of positive EBITDA.

Biome Australia Limited has reported a record-breaking quarter and half-year sales performance, driven by strong demand for its clinically-backed probiotic products. Revenue surged over 40% compared to the previous year, defying typical seasonal slowdowns.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.

Clover Corporation Limited reported a standout FY25 with robust revenue growth and a sharp rise in profitability, underpinned by strategic market expansion and product innovation. The company’s strengthened balance sheet and optimistic FY26 outlook signal continued momentum.